Management of cutaneous side effects of cetuximab therapy with vitamin K1 crème

Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7(Suppl 4): 2-8.10.1634/theoncologist.7-suppl_4-2Search in Google Scholar

Moosmann N, Heinemann V. Cetuximab in the treatment of metastatic colorectal cancer. Expert Opin Biol Ther 2007; 7: 243-56.10.1517/14712598.7.2.243Search in Google Scholar

Frieze DA, McCune JS. Current status of cetuximab for the treatment of patients with solid tumors. Ann Pharmacother 2006; 40: 241-50.10.1345/aph.1G191Search in Google Scholar

Summary of product characteristics. http://www.emea.europa.eu/humandocs/Humans/EPAR/erbitux/erbitux.htm;Search in Google Scholar

Smrdel U, Kovač V. Erlotinib in previously treated non-small-cell lung cancer. Radiol Oncol 2006; 40: 39-42.Search in Google Scholar

Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody. Drugs Today 2005; 41: 107-127.10.1358/dot.2005.41.2.882662Search in Google Scholar

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Eng J Med 2004; 351: 337-45.10.1056/NEJMoa033025Search in Google Scholar

Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 2008; 26: 5335-43.10.1200/JCO.2008.16.3758Search in Google Scholar

Scheiuthauer W, Sobrero A, Lenz HJ, Maurel J, Lutz M, Middleton G., et al. Cetuximab plus irinotecan in patients with mCRC who failed prior oxaliplatin-based therapy: the EPIC trial. [Abstract]. Eur J Cancer 2007; 5(4): 235.Search in Google Scholar

Van Cutsem E, Nowacki M, Lang I, Cascinu S, Schepotin I, Maurel J., et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. ASCO 2007. J Clin Oncol 2007; 25(18 Suppl): Abstract 4000.10.1200/jco.2007.25.18_suppl.4000Search in Google Scholar

Bokemeyer C, Staroslawska E, Makhson A, Bondarenko I, Hartmann JT, Shelygin Y, et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): a large-scale phase II study, OPUS. [Abstract]. Eur J Cancer 2007; 5(4): 236.10.1016/S1359-6349(07)70932-1Search in Google Scholar

Salz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM., et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer. The BOND-2 study. J Clin Oncol 2007; 25: 4516-8.Search in Google Scholar

Adam R, Aloia T, Levi F, de Haas RJ, Paule B, Bralet MP., et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic treatment. J Clin Oncol 2007; 25: 4593-602.10.1200/JCO.2007.10.8126Search in Google Scholar

Ciardiello F, Cervantes A, Vega-Villegas ME, Casado E, Rodriguez-Braun E, Martinelli E., et al. Optimal dose for an every 2 week (q2w) cetuximab (C) regimen in patients (pts) metastatic colorectal cancer (mCRC): a phase I safety, pharmacokinetics(PK) and pharmacodynamics (PD) study of weekly (q1w) add q2w schedules. [Abstract]. Eur J Cancer 2007; 5(4): 247.10.1016/S1359-6349(07)70968-0Search in Google Scholar

Pfeiffer P, Bjerregaard JK, Qvortrup C, Jensen BV, Yilmaz M, Nielsen D. Simplification of cetuximab (Cet) administration: double dose of every second week as a 60 minute infusion. J Clin Oncol 2007; 25(18 Suppl): Abstract 4133.10.1200/jco.2007.25.18_suppl.4133Search in Google Scholar

Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Eng J Med 2006; 354: 567-78.10.1056/NEJMoa05342216467544Search in Google Scholar

Burtness B, Goldwasser MA, Flood W, Mattar B, Forrastiere AA. Phase III randomized trial of cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23: 8646-54.10.1200/JCO.2005.02.464616314626Search in Google Scholar

Bourhis J, Rivera F, Mesia R, Awada A, Geoffrois L, Borel C., et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2866-72.10.1200/JCO.2005.04.354716717293Search in Google Scholar

Bernier J. Cetuximab in the treatment of head and neck cancer. Expert Rev Anticancer Ther 2006; 6: 1539-52.10.1586/14737140.6.11.153917134359Search in Google Scholar

Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8.10.1200/JCO.2004.10.18214993230Search in Google Scholar

Carson EJ, Novak AM, Stella PJ. Hypomagnesemia in patients with stage IV colorectal cancer treated with cetuximab as a single agent. [Abstract 3655]. Proc Am Soc Clin Oncol 2005; 24: 248-54.Search in Google Scholar

Vallbohmer D, Lenz HJ. Epidermal growth factor receptor as a target for chemotherapy. Clin Colorectal Cancer 2005; 5(Suppl 1): S19-27.10.3816/CCC.2005.s.003Search in Google Scholar

Damjanov N, Meropol NJ. Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled? Oncology 2004; 18: 479-88.Search in Google Scholar

Perez- Soler R, Zou Y, Li T, Tornos C, Ling Y. Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin. J Clin Oncol 2006; 24(18 Suppl): Abstract 3036.10.1200/jco.2006.24.18_suppl.3036Search in Google Scholar

National Cancer Institute. Common terminology criteria for adverse events v. 3.0 http://ctep.cancer.gov/reporting/ctc.htmlSearch in Google Scholar

Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the epidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144: 1169-76.10.1046/j.1365-2133.2001.04226.x11422037Search in Google Scholar

Segaert1 S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors Ann Oncol 2005; 16: 1425-33.10.1093/annonc/mdi27916012181Search in Google Scholar

Agero ALC, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatological side-effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55: 657-70.10.1016/j.jaad.2005.10.01017010747Search in Google Scholar

Galimont-Collen AFS, Vos LE, Lavrijsen APM, Ouwrkerk J, Gelderblom H. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007; 43: 845-51.10.1016/j.ejca.2006.11.01617289377Search in Google Scholar

Velenik V, Oblak I, Anderluh F. Quality of life in patients after combined modality treatment of rectal cancer: Report of a prospective phase II study. Radiol Oncol 2008: 42: 207-14.10.2478/v10019-008-0019-zSearch in Google Scholar